Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
The Food and Drug Administration (FDA) has expanded the approval of Humira (adalimumab) for the treatment of uveitis to include pediatric patients ≥2 years old.
The approval was based on data from a randomized, double-masked, placebo-controlled study of 90 pediatric patients aged 2 to <18 years with active JIA-associated non-infectious uveitis. Patients received either placebo (N=30) or adalimumab (N=60) 20mg (if <30kg) or 40mg (if ≥30kg) every other week in combination with a dose of methotrexate. The primary endpoint was “time to treatment failure,” defined as worsening or sustained non-improvement in ocular inflammation, or worsening of ocular co-morbidities.
Results showed that adalimumab significantly decreased the risk of treatment failure by 75% relative to placebo (hazard ratio: 0.25 [95% CI, 0.12, 0.49]).
The recommended dose of Humira for patients ≥2 years old with pediatric uveitis is based on weight; the treatment has not been studied in patients <2 years of age or in those with a weight <10kg.
In addition to uveitis, Humira, a tumor necrosis factor (TNF) blocker, is also approved to treat pediatric patients with juvenile idiopathic arthritis and Crohn’s disease.
For more information visit AbbVie.com.
